CoChat
Sign Up
Cited by 170Pharmacology and Obesity TreatmentObesity, Physical Activity, DietBariatric Surgery and Outcomes

Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials

Shi, Qingyang, Wang, Yang, Hao, Qiukui, Vandvik, Per Olav, Guyatt, Gordon, Li, Jing, Chen, Zhe, Xu, Shishi +20 more·2024·The Lancet
DOI 10.1016/s0140-6736(24)00351-9
Open this paper in CoChat — free account

Abstract

Background Pharmacotherapy provides an option for adults with overweight and obesity to reduce their bodyweight if lifestyle modifications fail. We summarised the latest evidence for the benefits and harms of weight-lowering drugs. Methods This systematic review and network meta-analysis included searches of PubMed, Embase, and Cochrane Library (CENTRAL) from inception to March 23, 2021, for randomised controlled trials of weight-lowering drugs in adults with overweight and obesity. We performed frequentist random-effect network meta-analyses to summarise the evidence and applied the Grading of Recommendations Assessment, Development, and Evaluation frameworks to rate the certainty of evidence, calculate the absolute effects, categorise interventions, and present the findings. The study was registered with PROSPERO, CRD 42021245678. Findings 14 605 citations were identified by our search, of which 132 eligible trials enrolled 48 209 participants. All drugs lowered bodyweight compared with lifestyle modification alone; all subsequent numbers refer to comparisons with lifestyle modification. High to moderate certainty evidence established phentermine-topiramate as the most effective in lowering weight (odds ratio [OR] of ≥5% weight reduction 8·02, 95% CI 5·24 to 12·27; mean difference [MD] of percentage bodyweight change -7·98, 95% CI -9·27 to -6·69) followed by GLP-1 receptor agonists (OR 6·33, 95% CI 5·00 to 8·00; MD -5·79, 95% CI -6·34 to -5·25). Naltrexone-bupropion (OR 2·69, 95% CI 2·10 to 3·44), phentermine-topiramate (2·40, 1·68 to 3·44), GLP-1 receptor agonists (2·22, 1·74 to 2·84), and orlistat (1·71, 1·42 to 2·05) were associated with increased adverse events leading to drug discontinuation. In a post-hoc analysis, semaglutide, a GLP-1 receptor agonist, showed substantially larger benefits than other drugs with a similar risk of adverse events as other drugs for both likelihood of weight loss of 5% or more (OR 9·82, 95% CI 7·09 to 13·61) and percentage bodyweight change (MD -11·40, 95% CI -12·51 to -10·29). Interpretation In adults with overweight and obesity, phentermine-topiramate and GLP-1 receptor agonists proved the best drugs in reducing weight; of the GLP-1 agonists, semaglutide might be the most effective. Funding 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(24)00351-9

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Incretin hormone-based drugs, first and foremost GLP-1RA, have emerged as a pivotal treatment option for managing both obesity and type 2 diabetes.

    “Among these, incretin hormone‐based drugs, first and foremost glucagon‐like peptide 1 receptor agonists (GLP‐1RA), 11 have emerged as a pivotal treatment option for managing both obesity and T2D. 12 , 13 , 14 , 15”

    From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer <scp>GLP</scp> ‐ <scp>1RA</scp> ‐based weight‐loss therapies (2025) · cites this paper as [15]

  • The three GLP-1RA-based agents currently approved for weight loss have all shown clear efficacy in promoting weight loss in randomized controlled trials.

    “The three GLP‐1RA‐based agents currently approved for weight loss have all shown clear efficacy in promoting weight loss in randomized controlled trials (RCTs), 17 , 18 , 19 that is, in settings with good medication adherence among participants and a follow‐up of typically one to two years. 15”

    From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer <scp>GLP</scp> ‐ <scp>1RA</scp> ‐based weight‐loss therapies (2025) · cites this paper as [15]

  • In a 2024 network meta-analysis of 61 randomized controlled trials, phentermine-topiramate (OR 2.40) and naltrexone-bupropion (OR 2.69) ranked among the highest for treatment discontinuation due to adverse events.

    “In a 2024 network meta-analysis of 61 randomized controlled trials (RCTs) comparing active treatments to lifestyle modification in adults with overweight or obesity, both phentermine-topiramate (odds ratio [OR]: 2.40, 95% CI 1.68, 3.44) and naltrexone-bupropion (OR: 2.69, 95% CI 2.10, 3.44) ranked among the highest for treatment discontinuation due to adverse events.14”

    From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [14]

  • GLP-1 RAs have primarily been associated with gastrointestinal side effects and have demonstrated more favorable psychiatric and cardiovascular safety profiles than alternative anti-obesity medications.

    “In contrast, GLP-1 RAs have primarily been associated with gastrointestinal side effects and have demonstrated more favorable psychiatric and cardiovascular safety profiles.13,14”

    From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [14]

  • Previous NMAs and a traditional meta-analysis on therapeutic options for overweight and obesity did not include more recently available OMMs such as tirzepatide, or included medications not approved for overweight/obesity, or adopted different inclusion criteria.

    “Several NMAs20–23 and a traditional meta-analysis24 on different therapeutic options for overweight and obesity were published in the last few years, but they did not include more recently available OMMs, such as tirzepatide20–22, or they included medications not approved for the treatment of overweight/obesity (for example, metformin, SGLT2 inhibitors or GLP-1 agonists, such as dulaglutide)22, or”

    From A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults (2025) · cites this paper as [22]

Cites

Flagged first, then by citations

1 of the 43 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Shi, Q., Wang, Y., Hao, Q., Vandvik, P. O., Guyatt, G., Li, J., Chen, Z., Xu, S., Shen, Y., Ge, L., Sun, F., Li, L., Yu, J., Nong, K., Zou, X., Zhu, S., Wang, C., Zhang, S., Qiao, Z., Jian, Z., Li, Y., Zhang, X., Chen, K., Qu, F., Wu, Y., He, Y., Tian, H., & Li, S.
Affiliations
  • Sichuan University (CN)
  • Lovisenberg Diakonale Sykehus (NO)
  • McMaster University (CA)
  • Tianjin University of Traditional Chinese Medicine (CN)
  • Lanzhou University (CN)
  • Peking University (CN)
  • First Affiliated Hospital of Xi'an Jiaotong University (CN)
Corresponding author
Li, Sheyu
ORCID
Venue
The Lancet
Publisher
Elsevier BV
Published
2024-04
Volume
403
Issue
10434
Pages
e21-e31
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(24)00351-9
OpenAlex
W4393952591
Cited by
155
References
43
Citations by year
2026: 60 · 2025: 67 · 2024: 27 · 2022: 1
FWCI
9.65
Type
journal article
Language
en
Update notices
erratum (2024-04-06)
Open access
closed
Licence
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
West China Hospital, Sichuan University (ZYGD18022, 2020HXF011)
Topics
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
pharmacotherapy, obesity, overweight, phentermine/topiramate, GLP-1 receptor agonists, semaglutide, naltrexone/bupropion, orlistat, lifestyle modification, weight loss, adverse events, drug discontinuation, adults, GRADE certainty of evidence
MeSH terms
Network Meta-Analysis, Topiramate, Adult, Humans, Obesity, Phentermine, Weight Loss, Randomized Controlled Trials as Topic, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review